Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
In recent times, there has been a significant expansion in the size of the Duchenne Muscular Dystrophy (DMD) therapeutics market. The market is projected to surge from $11.95 billion in 2024 to $16.45 billion in 2025, growing at a Compound Annual Growth Rate (CAGR) of 37.6%. The substantial growth observed in the historical period is due to the rising incidence of Duchenne Muscular Dystrophy, heightened awareness around its treatment, increased healthcare expenditure, and government initiatives.
What Growth Rate Is Forecasted for the Duchenne Muscular Dystrophy (DMD) Therapeutics Market by 2029?
The size of the Duchenne muscular dystrophy (DMD) therapeutics market is predicted to undergo significant growth in the upcoming years. It is projected to expand to a value of $47.34 billion in 2029, with a compound annual growth rate (CAGR) of 30.3%. The predicted growth during the forecast period can be accredited to increasing investments in Duchenne muscular dystrophy treatments, uptake of combination therapies, evolution of biomarkers, and increased screening programs for Duchenne muscular dystrophy. Some notable trends during this forecast period encompass the introduction of innovative treatments for Duchenne muscular dystrophy, the creation of targeted therapies, the launch of novel medications and therapies, pioneering disease-modifying therapies, and vigorous drug developments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Which Key Companies Are Shaping the Future of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Which Factors Are Driving Demand in the Duchenne Muscular Dystrophy (DMD) Therapeutics Industry?
Expected advancements in the Duchenne muscular dystrophy (DMD) therapeutics market are set to be fueled by an increase in clinical trials. These trials, performed on human test subjects to assess the safety and efficiency of new medical interventions or drugs, help inspire innovation, research, and a wider range of potential treatment methods for Duchenne muscular dystrophy. Such developments should improve patient prognosis, attract more investment, and speed up the progress and accessibility of effective therapies for DMD. Statistics from Clinicaltrials.Gov, related to The National Institutes Of Health (NIH), in August 2023 indicate that registered clinical trials rose to 464,218 from 399,496 in 2021 across all 50 U.S states and 221 countries. Importantly, 142,700 studies were reported in the U.S. (31% of the total), while 248,310 studies were documented in non-U.S. locations (53% of the total). Therefore, the growth of the Duchenne muscular dystrophy (DMD) therapeutics market can be expected, in part, due to the increasing number of clinical trials. Observations clearly show the Duchenne Muscular Dystrophy (DMD) market has growing scope due to the rapid rise in genetic disorders. Characterised by the mutations or irregularities in a person’s genetic material or DNA, genetic disorders tend to become an impetus for the DMD market. This is because an increase in genetic disorders means more individuals are at risk of developing DMD, hence, creating a demand for DMD diagnostic, treatment, and therapeutic solutions. To illustrate, the World Health Organization (WHO) reported in February 2022 that annually, birth anomalies cause the deaths of approximately 240,000 newborns within their first 28 days of life. In addition, another 170,000 children between 1 month to 5 years die due to birth defects, including neural tube defects, heart defects, and Down syndrome. Consequently, the rising incidence of genetic disorders is seen to be driving the growth of the Duchenne muscular dystrophy (DMD) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
How Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmented by Several Divisions?
The duchenne muscular dystrophy (DMD) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
What are the Emerging Market Trends Driving the Growth of the Duchenne Muscular Dystrophy (DMD) Therapeutics Industry?
Leading enterprises in the duchenne muscular dystrophy (DMD) therapeutics market are embracing innovative technologies to improve the effectiveness and availability of DMD treatments, thereby maintaining their market presence. In an example, Bit Bio Ltd., a synthetic biology firm from the UK, rolled out disease model products in July 2023 to aid the enhancement of Duchenne muscular dystrophy (DMD) treatments. These disease models, called ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes featuring genetically manipulated deletions in the gene linked to dystrophin protein production. These models by Bit Bio, which are reconfigured from induced pluripotent stem cells (iPSCs), offer a reliable and expandable source of human cells for academic study, thereby tackling issues related to variability and primary cell sourcing. These inventories aid in the progression of DMD treatments, offering deeper understanding into disease processes and potential therapeutic strategies. This breakthrough could fast-track the efforts of researchers in pursuit of efficient DMD treatments.
Access The Full Report Here:
Which Regions Are Driving Growth in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12916
This Report Delivers Insight On:
1. How big is the duchenne muscular dystrophy (dmd) therapeutics market, and how is it changing globally?
2. Who are the major companies in the duchenne muscular dystrophy (dmd) therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the duchenne muscular dystrophy (dmd) therapeutics market right now?
4. Which products or customer segments are growing the most in the duchenne muscular dystrophy (dmd) therapeutics market?
5. What factors are helping or slowing down the growth of the duchenne muscular dystrophy (dmd) therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
